乳腺癌转移灶的克隆重塑与亚型转换相关
该研究分析了57对原发与转移性乳腺癌样本,发现转移灶突变癌症细胞分数(CCF)显著高于原发灶,且克隆重塑在发生临床亚型转换的转移灶中更明显,提示亚型变化与肿瘤进化中的克隆重塑相关。
要点
- 转移灶突变CCF中位0.51高于原发灶0.47(P=0.042),提示克隆同质性增加。
- 临床亚型转换见于24.6%转移灶,内在亚型转换见于36.9%。
- CCF升高在临床亚型转换组显著(P=0.04),内在亚型转换组不显著(P=0.48)。
核心结论
- 乳腺癌转移灶突变CCF显著高于原发灶,亚型转换与克隆重塑相关。
研究设计与样本
- 研究纳入GEICAM/2009-03研究57对原发与转移性乳腺癌样本,对202个基因进行靶向捕获测序。
主要发现
- 临床亚型转换发生于24.6%的转移灶,内在亚型转换发生于36.9%的转移灶。
- 原发灶与转移灶突变数中位分别为11(范围3-29)和9(范围1-38),P=0.05。
- 转移灶突变CCF中位0.51高于原发灶0.47(P=0.042)。
- CCF升高在临床亚型转换组显著(P=0.04),在内在亚型转换组不显著(P=0.48)。
- 激素受体阳性且HER2阳性肿瘤的转移灶克隆重塑最高(P=0.006)。
临床怎么用
- 对乳腺癌转移灶应重新评估临床与内在亚型,关注亚型转换可能伴随的克隆重塑。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Changes in the clinical subtype (CS) and intrinsic subtype (IS) between breast cancer (BC) metastases and corresponding primary tumours have been reported. However, their relationship with tumour genomic changes remains poorly characterised. Here, we analysed the association between genomic remodelling and subtype conversion in paired primary and metastatic BC samples. METHODS: A total of 57 paired primary and metastatic tumours from GEICAM/2009-03 (ConvertHER, NCT01377363) study participants with centrally assessed CS (n = 57) and IS (n = 46) were analysed. Targeted capture and next-generation sequencing of 202 genes on formalin-fixed paraffin-embedded samples was performed. The cancer cell fraction (CCF) of mutations in primary and metastatic pairs was estimated as a surrogate of tumour clonal architecture. Changes in mutation CCF between matched primary and metastatic tumours were analysed in the presence or absence of subtype conversion. FINDINGS: CS conversion occurred in 24.6% and IS conversion occurred in 36.9% of metastases. Primary tumours and metastases had a median of 11 (range, 3-29) and 9 (range, 1-38) mutations, respectively (P = 0.05). Overall, mutations in metastases showed a higher estimated CCF than in primary tumours (median CCF, 0.51 and 0.47, respectively; P = 0.042), consistent with increased clonal homogeneity. The increase in mutation CCF was significant in CS-converted (P = 0.04) but not in IS-converted (P = 0.48) metastases. Clonal remodelling was highest in metastases from hormone receptor-positive and human epidermal growth factor 2 (HER2)-positive tumours (P = 0.006). CONCLUSIONS: Mutations in BC metastases showed significantly higher estimated CCF than primary tumours. CCF changes were more prominent in metastases with CS conversion. Our findings suggest that changes in BC subtypes are linked to clonal remodelling during BC evolution.
引用
- Lluch A, González-Angulo AM, Casadevall D, et al. Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversion. Eur J Cancer. 2019. PMID: 31491604. doi:10.1016/j.ejca.2019.07.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。